{"id":"lodac","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression / neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea / vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LoDAC (low-dose cytarabine) is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA during the S phase of the cell cycle, leading to cell death. The low-dose formulation aims to optimize the therapeutic window by reducing toxicity while maintaining anti-leukemic activity, particularly in elderly or unfit patients who cannot tolerate standard chemotherapy doses.","oneSentence":"LoDAC is a low-dose cytarabine formulation designed to improve tolerability and efficacy in hematologic malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:20.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) in elderly or unfit patients"},{"name":"Myelodysplastic syndrome (MDS)"}]},"trialDetails":[{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT05766514","phase":"PHASE2","title":"Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2025-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT05698966","phase":"NA","title":"Low Dose Antenatal Corticosteroids for Late Preterm Delivery","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2022-01-01","conditions":"Respiratory Morbidity, Preterm Labor","enrollment":1510},{"nctId":"NCT05876832","phase":"PHASE3","title":"A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)","status":"NOT_YET_RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2023-06-15","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":312},{"nctId":"NCT04716114","phase":"PHASE3","title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-03-24","conditions":"Acute Myeloid Leukemia (AML)","enrollment":315},{"nctId":"NCT05100303","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-12","conditions":"Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT02039726","phase":"PHASE3","title":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-05","conditions":"AML","enrollment":367}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low Dose Cytarabine"],"phase":"phase_3","status":"active","brandName":"LoDAC","genericName":"LoDAC","companyName":"Sunshine Lake Pharma Co., Ltd.","companyId":"sunshine-lake-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LoDAC is a low-dose cytarabine formulation designed to improve tolerability and efficacy in hematologic malignancies. Used for Acute myeloid leukemia (AML) in elderly or unfit patients, Myelodysplastic syndrome (MDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}